Jessica L. Taylor, MD is an Assistant Professor of Medicine in General Internal Medicine at the Chobanian and Avedisian School of Medicine and Boston Medical Center and a board-certified Addiction Specialist. She attended Mount Sinai School of Medicine and completed internal medicine residency training at Beth Israel Deaconess Medical Center and Harvard Medical School, where she also served as a Chief Resident. Dr. Taylor’s clinical work focuses on the care of patients with substance use disorders, HIV, and viral hepatitis.
Her research interests include HIV prevention among people who inject drugs, HIV pre-exposure prophylaxis (PrEP) implementation, low-barrier substance use disorder treatment models, and overdose prevention. She is Co-Director of the Care Continuum Core for the Massachusetts site of the NIDA-funded Healing Communities Study, which aims to reduce fatal opioid overdose by 40%.
Dr. Taylor is the Medical Director of Faster Paths to Treatment, Boston Medical Center’s innovative, low-barrier substance use disorder bridge clinic and the Medical Director of the Transitional Care Clinic, a bridge clinic co-located with a low-threshold, transitional housing program for people experiencing homelessness. She directs HIV Prevention Programs at BMC. Her educational roles include directing the HIV Pathway for internal medicine residents and serving as core faculty in BUSM’s Addiction Medicine fellowship program.
- Faculty, Clinical Addiction Research and Education Unit, Medicine, Boston University Chobanian & Avedisian School of Medicine
- Mount Sinai School of Medicine, MD
- Duke University, BS
- Published on 7/29/2022
Weisenthal K, Kimmel SD, Kehoe J, Larochelle MR, Walley AY, Taylor JL. Effect of police action on low-barrier substance use disorder service utilization. Harm Reduct J. 2022 Jul 29; 19(1):86. PMID: 35906660.
- Published on 7/1/2022
Streed CG, Morgan JR, Gai MJ, Larochelle MR, Paasche-Orlow MK, Taylor JL. Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons With Commercial Insurance and Likely Injection Drug Use. JAMA Netw Open. 2022 Jul 01; 5(7):e2221346. PMID: 35819784.
- Published on 5/14/2022
Taylor JL, Laks J, Christine PJ, Kehoe J, Evans J, Kim TW, Farrell NM, White CS, Weinstein ZM, Walley AY. Bridge clinic implementation of "72-hour rule" methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care. Drug Alcohol Depend. 2022 Jul 01; 236:109497. PMID: 35607834.
- Published on 2/7/2022
Alves J, Stewart J, Ruiz-Mercado G, Taylor JL. When Perfect Is the Enemy of Tested: a Call to Scale Rapid HIV Testing for People Who Inject Drugs. J Gen Intern Med. 2022 Aug; 37(11):2851-2852. PMID: 35132547.
- Published on 1/11/2022
Taylor JL, Samet JH. Opioid Use Disorder. Ann Intern Med. 2022 01; 175(1):ITC1-ITC16. PMID: 35007147.
- Published on 1/1/2022
Bonner R, Stewart J, Upadhyay A, Bruce RD, Taylor JL. A Primary Care Intervention to Increase HIV Pre-Exposure Prophylaxis (PrEP) Uptake in Patients with Syphilis. J Int Assoc Provid AIDS Care. 2022 Jan-Dec; 21:23259582211073393. PMID: 35001723.
- Published on 12/28/2021
Laks J, Kehoe J, Farrell NM, Komaromy M, Kolodziej J, Walley AY, Taylor JL. Methadone initiation in a bridge clinic for opioid withdrawal and opioid treatment program linkage: a case report applying the 72-hour rule. Addict Sci Clin Pract. 2021 12 28; 16(1):73. PMID: 34961554.
- Published on 11/1/2021
Harvey L, Taylor JL, Assoumou SA, Kehoe J, Schechter-Perkins EM, Bernstein E, Walley AY. Sexually Transmitted and Blood-borne Infections Among Patients Presenting to a Low-barrier Substance Use Disorder Medication Clinic. J Addict Med. 2021 Nov-Dec 01; 15(6):461-467. PMID: 34734572.
- Published on 11/1/2021
Komaromy M, Tomanovich M, Taylor JL, Ruiz-Mercado G, Kimmel SD, Bagley SM, Saia KM, Costello E, Park TW, LaBelle C, Weinstein Z, Walley AY. Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic. J Addict Med. 2021 Nov-Dec 01; 15(6):448-451. PMID: 33298750.
- Published on 6/22/2021
Taylor JL, Johnson S, Cruz R, Gray JR, Schiff D, Bagley SM. Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment. J Gen Intern Med. 2021 12; 36(12):3810-3819. PMID: 34159545.
View 16 more publications: View full profile at BUMC